Safety and efficacy of lenvatinib in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice

被引：0
|
作者：
Ogushi, Katsuaki [1 ]
Chuma, Makoto [1 ]
Numata, Kazushi [1 ]
Uojima, Haruki [2 ]
Hidaka, Hisash [2 ]
Nakazawa, Takashi [2 ]
Hirose, Shunji [3 ]
Kagawa, Tatehiro [3 ]
Matsunaga, Koutarou [4 ]
Hattori, Nobuhiro [4 ]
Kobayashi, Satoshi [5 ]
Morimoto, Manabu [5 ]
Fukushima, Taito [5 ]
Iwabuchi, Shogo [6 ]
Fujikawa, Tomoaki [6 ]
Kako, Makoto [7 ]
Tanaka, Katsuaki [8 ]
Maeda, Shin [9 ]
机构：
[1] Yokohama City Univ, Med Ctr, Gastroenterol, Yokohama, Kanagawa, Japan
[2] Kitasato Univ Hosp, Gastroenterol, Sagamihara, Kanagawa, Japan
[3] Tokai Univ Hosp, Gastroenterol, Isehara, Kanagawa, Japan
[4] St Marianna Univ, Sch Med Hosp, Gastroenterol & Hepatol, Kawasaki, Kanagawa, Japan
[5] Kanagawa Canc Ctr, Gastroenterol, Yokohama, Kanagawa, Japan
[6] Shonan Fujisawa Tokushukai Hosp, Gastroenterol, Fujisawa, Kanagawa, Japan
[7] Shonan Kamakura Gen Hosp, Gastroenterol, Kamakura, Kanagawa, Japan
[8] Japanese Red Cross Hadano Hosp, Gastroenterol, Hadano, Japan
[9] Yokohama City Univ Med, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT495
引用
收藏
页码：S901 / S903
页数：3
相关论文
共 50 条
  • [31] Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study
    Ishii, Masatsugu
    Itano, Osamu
    Iwamoto, Hideki
    Hibi, Taizo
    Itano, Satoshi
    ONCOLOGY, 2022, 100 (05) : 278 - 289
  • [32] Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings
    Ohama, Hideko
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Naganuma, Atsushi
    Kosaka, Hisashi
    Matono, Tomomitsu
    Shibata, Hiroshi
    Aoki, Tomoko
    Tada, Fujimasa
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Iijima, Hiroko
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    Kumada, Takashi
    ONCOLOGY, 2023, 101 (09) : 542 - 552
  • [33] Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patients
    Kim, Hyeyeong
    Cheon, Jaekyung
    Ha, Yeongjung
    Kim, Han Sang
    Kim, Chang Gon
    Kim, Ilhwan
    Kim, Chan
    Jung, Sang-Hoon
    Chon, Hong Jae
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [34] Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
    Kang, W.
    Kim, J.
    Kim, S. U.
    Seo, Y-S.
    Kim, J.
    Kim, J-H.
    Park, S. Y.
    Baek, Y-H.
    Kim, K.
    Lee, H. L.
    Yoon, K. T.
    Kim, H.
    Cheong, J. Y.
    Hwang, J. S.
    Kim, J. H.
    Kim, K. M.
    Sung, P. S.
    Kim, J. J.
    Kim, D-Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S609 - S609
  • [35] Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma
    Cheon, Jaekyung
    Kim, Hyeyeong
    Kim, Han Sang
    Kim, Chang Gon
    Kim, Ilhwan
    Kang, Beodeul
    Kim, Chan
    Jung, Sanghoon
    Ha, Yeonjung
    Chon, Hong Jae
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [36] CHILD-PUGH (B) -NON-ENCEPHALOPATHIC PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA MAY BENEFIT FROM METRONOMIC CAPECTIABINE
    Shaltout, Ehab
    Abd El Razek, Eman
    ANNALS OF ONCOLOGY, 2012, 23 : 56 - 56
  • [37] Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series
    Kambhampati, Swetha
    Bauer, Kelly E.
    Bracci, Paige M.
    Keenan, Bridget P.
    Behr, Spencer C.
    Gordan, John D.
    Kelley, Robin K.
    CANCER, 2019, 125 (18) : 3234 - 3241
  • [38] Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib
    Huynh, J.
    Cho, M.
    Kim, E.
    Ren, M.
    Amaya-Chanaga, C.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S123 - S124
  • [39] Analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) and Child-Pugh (CP)-B liver function treated with regorafenib in routine clinical practice in the observational REFINE study
    Kim, Yoon Jun
    Merle, Philippe
    Finn, Richard S.
    Kudo, Masatoshi
    Klumpen, Heinz-Josef
    Lim, Ho Yeong
    Pinter, Matthias
    Babajanyan, Svetlana
    Khan, Javeed
    Awan, Maria
    Ozgurdal, Kirhan
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 452 - 452
  • [40] Clinical impact of carbon ion radiotherapy for hepatocellular carcinoma with Child-Pugh B cirrhosis
    Hiroshima, Y.
    Wakatsuki, M.
    Kaneko, T.
    Makishima, H.
    Ishikawa, H.
    Tsuji, H.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1083 - S1084
12345